Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: 2 - You Need To See This

Tilray Eyes Reverse Stock Split As Nasdaq Listing Compliance Pressure Mounts

Tilray Brands, Inc. (NASDAQ:TLRY) shares slipped Thursday after the company said it is seeking more time from Nasdaq to restore compliance with the exchange’s continued listing rules tied to its per-share price.

Benzinga

Why This Cannabis Penny Stock Could Be Wall Street’s Next Meme Trade Breakout

When cannabis stocks exploded this week, Tilray Brands (TLRY) wasn’t just along for the ride - it could be setting up for meme stock status.

Barchart

What's Going On With Tilray Stock Today?

Tilray Brands, Inc. (NASDAQ:TLRY) shares are trading higher on Tuesday.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Tilray Surges 14% After Hours On Trump Cannabis Reclassification

Tilray Brands Inc. (NASDAQ:TLRY) stock surged by 14.13%, to $1.05 during after-hours on Monday. This surge follows a report suggesting that President Donald Trump is contemplating reclassifying marijuana, a move that could significantly impact the industry.

Benzinga

While Investors Chase Monday's Tilray, Canopy And Aurora Rally, A Potential Federal Shift Could Redefine Cannabis Growth Fundamentals

Shares of major cannabis companies, including Tilray Brands Inc (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), and Aurora Cannabis Inc (NASDAQ:ACB), are trading sharply higher Monday morning.

Benzinga

Following Mixed Q4 Results, Tilray's Turnaround Strategy Is Put To The Test

Shares of Tilray Brands Inc (NASDAQ:TLRY) are trading lower Tuesday morning after the global cannabis and consumer goods company reported fourth-quarter revenue that fell short of analyst expectations. Here’s what investors need to know.

Benzinga

Tilray Misses Q4 Revenue, Beats EPS Estimates, Shares Slide

Tilray Brands Inc (NASDAQ:TLRY) reported fourth-quarter financial results for fiscal 2025 after the market close on Monday. Here’s a rundown of the report.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

MarketBeat Week in Review – 07/14 - 07/18

The NASDAQ and S&P 500 hit all-time highs on better-than-expected economic data; the market is confirming expectations for a strong second half

MarketBeat

Tilray Shares Blazing: What's Behind the 55% Rally This Month?

Tilray's recent 55% rally may draw investor attention, but do the potential benefits outweigh the continued risks of this cannabis leader?

MarketBeat

Tilray Brands Stock Is Climbing Monday: What's Driving The Action?

Shares of Tilray Brands Inc (NASDAQ:TLRY) are trading higher Monday morning, building on a recent rally fueled by heavy trading volume and company announcements. The cannabis giant’s stock has been a focal point for investors in recent sessions, driven by a combination of high short interest and positive industry news.

Benzinga

What's Going On With Tilray Brands Stock?

Shares of Tilray Brands Inc (NASDAQ:TLRY) are surging higher Wednesday, extending a recent rally on heavy trading volume. Here’s what investors need to know.

Benzinga

Tilray (TLRY) Stock Surges On Heavy Volume: What Investors Should Know

Shares of Tilray Brands Inc (NASDAQ:TLRY) are trading sharply higher Tuesday afternoon, continuing a recent trend of investor interest across social media despite a lack of company-specific news for the session. Here’s what investors need to know.

Benzinga

What's Going On With Tilray Brands Stock Today?

Tilray Brands Inc (NASDAQ:TLRY) stock is trending across social media Thursday, despite a lack of fresh company-specific news for the session. The cannabis and consumer brands company made several strategic moves in June that could be fueling the current interest.

Benzinga

Is Tilray Stock a Buy on Positive Cannabis Data?

Tilray reported a positive update for its chemo-related drug.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

1 Cannabis Stock I Would Buy, and One I Would Avoid

The cannabis industry is rapidly growing, but will Canadian players be able to keep up?

Barchart

Cresco vs. Tilray: Which Cannabis Stock Is a Better Buy?

Despite lingering regulatory challenges, the cannabis market is well-positioned for a steady expansion. Penny stock Cresco's solid financials and growth potential have won over analysts, while Tilray failed to impress with last quarter’s record revenue.

StockNews.com

Cannabis Check: Should You Consider Canopy Growth (CGC) and Tilray (TLRY) for Your 2024 Portfolio?

The cannabis industry is undergoing a turbulent time due to legalization troubles and its struggles to realize gains. Amid this, would it be wise to invest in Tilray Brands (TLRY) and Canopy Growth (CGC) this year? Keep reading….

StockNews.com

Tilray Brands (TLRY) Earnings Spotlight -- Buy or Sell?

Tilray Brands (TLRY) posted record net revenue in its most recent quarter. So, is this the right entry point in the stock? Let’s analyze some of its key financial metrics to gauge its prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Bullish or Bearish: 3 Pharma Options

The pharmaceutical industry’s robust outlook is driven by high healthcare spending globally, consistent R&D efforts, and the rapid adoption of advanced digital technologies. So, let’s analyze if investors should adopt a bullish or bearish stance on pharma stocks such as Tilray Brands (TLRY), CytomX Therapeutics (CTMX), and Wave Life Sciences…

StockNews.com

Is Tilray Brands (TLRY) a Possible Buy Opportunity Before Earnings?

Tilray Brands (TLRY) holds the leadership position in the cannabis market of Canada. Additionally, it is making forays into the beverages market to spur its growth. However, the federal legalization of cannabis in the United States is still some time away. With the company scheduled to release its earnings on…

StockNews.com

Tilray Brands (TLRY) vs. Novo Nordisk (NVO): Which Pharma Stock Should You Buy?

The pharmaceutical sector performs relatively well during economic uncertainties due to inelastic demand for its products and services. While prominent players Tilray Brands (TLRY) and Novo Nordisk (NVO) should benefit, which stock is the better buy now? Read more to find out.

StockNews.com

Should You Add Shares of Tilray Brands (TLRY) to Your Portfolio?

Canadian cannabis leader Tilray Brands (TLRY) is bolstering its portfolio through expansions and partnerships. However, the company’s recent $150 million offering of senior notes put pressure on its stock price. Would it be wise to buy the stock now? Let’s look at its financial metrics to answer that….

StockNews.com

3 Cannabis Stocks to Avoid Despite the Legalization Momentum in 2023

Despite legalization gaining traction, the cannabis industry's prospects for the year ahead remain grim due to several economic and industry-wide headwinds. As a result, it seems wise to avoid sinking cannabis stocks Curaleaf Holdings (CURLF), Tilray Brands (TLRY), and Verano Holdings (VRNOF). Read more….

StockNews.com

2 Cannabis Stocks to Think Twice About Before Buying

The cannabis industry has been facing several economic and regulatory challenges. Demand has also slowed amid a glut in supply. With the Fed unlikely to stop interest rate hikes, the economy could enter a recession this year. Amid this backdrop, it could be wise to avoid fundamentally weak cannabis stocks…

StockNews.com

Sell the Farm on These 4 Cannabis Stocks

Despite significant growth in recent years driven by increased legalization, the cannabis industry took a hit last year amid economic and industry-wide headwinds, including stubborn supply gluts. Furthermore, the industry will likely remain under pressure this year due to economic challenges. Hence, it could be wise to avoid fundamentally weak…

1 2 3 4 5

People

Dipanjan BanchurSince

Gabriel OsorioMazilli

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

125 stories

TLRY

105 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.